Literature DB >> 11368514

Type I collagen stabilization of matrix metalloproteinase-2.

S M Ellerbroek1, Y I Wu, M S Stack.   

Abstract

The activity of matrix metalloproteinase-2 (MMP-2) is regulated stringently on the posttranslational level. MMP-2 efficiently undergoes autolysis into inactive polypeptides in vitro, prompting the hypothesis that MMP-2 autolysis may function as an alternative mechanism for posttranslational control of MMP-2 in vivo. Moreover, MMP-2 binds to intact type I collagen fibrils; however, the functional consequences of this interaction have not been fully elucidated. To test the hypothesis that MMP-2 binding to type I collagen functions as a positive regulator of MMP-2 proteolytic potential, the effect of type I collagen on MMP-2 activity, inhibition by tissue inhibitor of metalloproteinase-2 (TIMP-2), and enzyme stability was examined. Here, we report that purified MMP-2 binds but does not cleave intact type I collagen. The presence of type I collagen affects neither enzymatic activity against a quenched fluorescent peptide substrate nor the kinetics of inhibition by TIMP-2. However, MMP-2 is stabilized from autolysis in the presence of type I collagen, but not by elastin, fibrinogen, or laminin. These data provide biochemical evidence that MMP-2 exosite interactions with type I collagen may function in the posttranslational control of MMP-2 activity by reducing the rate of autolytic inactivation. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11368514     DOI: 10.1006/abbi.2001.2345

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

Review 1.  Cystatin superfamily.

Authors:  Josiah Ochieng; Gautam Chaudhuri
Journal:  J Health Care Poor Underserved       Date:  2010-02

Review 2.  Myocardial matrix metalloproteinase-2: inside out and upside down.

Authors:  Ashley DeCoux; Merry L Lindsey; Francisco Villarreal; Ricardo A Garcia; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

3.  Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma.

Authors:  Maria V Barbolina; Mijung Kim; Yueying Liu; Jaclyn Shepard; Abdelhak Belmadani; Richard J Miller; Lonnie D Shea; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2010-05-11       Impact factor: 5.852

4.  Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma.

Authors:  Maria V Barbolina; Brian P Adley; David L Kelly; Angela J Fought; Denise M Scholtens; Lonnie D Shea; M Sharon Stack
Journal:  Lab Invest       Date:  2008-03-24       Impact factor: 5.662

Review 5.  Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis.

Authors:  Maria V Barbolina; M Sharon Stack
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

6.  The synthetic hydroxyproline-containing collagen analogue (Gly-Pro-Hyp)10 promotes enzymatic activity of matrixmetalloproteinase-2 in vitro.

Authors:  C Freise; M Ruehl; U Erben; R W Farndale; R Somasundaram; M M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

7.  Hydroxyproline-containing collagen analogs trigger the release and activation of collagen-sequestered proMMP-2 by competition with prodomain-derived peptide P33-42.

Authors:  Martin Ruehl; Marion Muche; Christian Freise; Ulrike Erben; Ulf Neumann; Detlef Schuppan; Yury Popov; Walburga Dieterich; Martin Zeitz; Richard W Farndale; Rajan Somasundaram
Journal:  Fibrogenesis Tissue Repair       Date:  2011-01-06

8.  Hepatic stellate cells' involvement in progenitor-mediated liver regeneration.

Authors:  Dana G Pintilie; Thomas D Shupe; Seh-hoon Oh; Susan V Salganik; Houda Darwiche; Bryon E Petersen
Journal:  Lab Invest       Date:  2010-05-03       Impact factor: 5.662

Review 9.  Journey of cystatins from being mere thiol protease inhibitors to at heart of many pathological conditions.

Authors:  Anas Shamsi; Bilqees Bano
Journal:  Int J Biol Macromol       Date:  2017-04-23       Impact factor: 6.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.